Viewing Study NCT01035502

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:05 AM
Ignite Modification Date: 2026-06-19 @ 6:56 PM
Study NCT ID: NCT01035502
Status: COMPLETED
Last Update Posted: 2013-09-27
First Post: 2009-12-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Sponsor: Clavis Pharma
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Cancer View
None CP-4055 View
None elacytarabine View
None combination View
None idarubicin View
None Acute myeloid leukaemia (AML) View